Search: onr:"swepub:oai:DiVA.org:uu-11010" >
Longitudinal stabil...
Longitudinal stability of CSF biomarkers in Alzheimer's disease
-
- Blennow, Kaj, 1958 (author)
- Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry
-
- Zetterberg, Henrik, 1973 (author)
- Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry
-
- Minthon, Lennart (author)
- Lund University,Lunds universitet,Klinisk minnesforskning,Forskargrupper vid Lunds universitet,Clinical Memory Research,Lund University Research Groups
-
show more...
-
- Lannfelt, Lars (author)
- Uppsala universitet,Institutionen för folkhälso- och vårdvetenskap,Geriatrics
-
Strid, Stig (author)
-
- Annas, Peter (author)
- Karolinska Institutet
-
- Basun, Hans (author)
- Uppsala universitet,Institutionen för folkhälso- och vårdvetenskap
-
- Andreasen, Niels (author)
- Karolinska Institutet
-
show less...
-
(creator_code:org_t)
- Elsevier BV, 2007
- 2007
- English.
-
In: Neuroscience Letters. - : Elsevier BV. - 0304-3940 .- 1872-7972. ; 419:1, s. 18-22
- Related links:
-
http://dx.doi.org/10...
-
show more...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
https://lup.lub.lu.s...
-
https://gup.ub.gu.se...
-
http://kipublication...
-
show less...
Abstract
Subject headings
Close
- Biomarker levels in cerebrospinal fluid (CSF) may serve as surrogate markers for treatment efficacy in clinical trials of disease-modifying drugs against Alzheimer's disease (AD). A prerequisite, however, is that the marker is sufficiently stable over time in individual patients. Here, we tested the stability of the three established CSF biomarkers for AD, total tau (T-tau), tau phosphorylated at threonine 181 (P-tau181) and the 42 amino acid isoform of β-amyloid (Aβ42), over 6 months in a cohort of AD patients on stable treatment with acetylcholinesterase (AChE) inhibitors. Fifty-three patients completed the study, 29 men and 24 women, mean age (±S.D.) 76.1 ± 7.9 years. Mean levels of CSF biomarkers were very stable between baseline and endpoint, with coefficients of variation (CVs) of 4.4–6.1%. Intra-individual biomarker levels at baseline and endpoint were also highly correlated with Pearson r-values above 0.95 (p < 0.0001), for all three markers. We conclude that T-tau, P-tau and Aβ42 concentrations in CSF are remarkably stable over a 6-month period in individual AD patients. This suggest that these biomarkers may have a potential to identify and monitor very minor biochemical changes induced by treatment, and thus support their possible usefulness as surrogate markers in clinical trials with drug candidates with disease-modifying potential, such as secretase inhibitors, Aβ immunotherapy and tau phosphorylation inhibitors.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper -- Neurovetenskaper (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Basic Medicine -- Neurosciences (hsv//eng)
Keyword
- Biomarkers
- β-Amyloid
- Cerebrospinal fluid (CSF)
- Clinical trials
- Longitudinal
- Tau protein
- MEDICINE
- MEDICIN
- clinical trials
- cerebrospinal fluid (CSF)
- biomarkers
- beta-amyloid
- tau protein
- longitudinal
- cerebrospinal-fluid levels
- tau-protein
- in-vivo
- inhibitors
- ad
- acetylcholinesterase
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database